Compare Recursion Pharmaceuticals Inc (RXRX) vs Williams-Sonoma, Inc. (WSM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Williams-Sonoma, Inc. — how do they compare? Recursion Pharmaceuticals Inc trades at $4 (market cap $2.14B), while Williams-Sonoma, Inc. trades at $239 (market cap $28.15B). The key difference: Williams-Sonoma, Inc. is far larger — about 13.2× Recursion Pharmaceuticals Inc's market cap, and Williams-Sonoma, Inc. pays a 1.27% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Recursion Pharmaceuticals Inc for 22 Days and Williams-Sonoma, Inc. for 59 Days on average.
| RXRX | WSM | |
|---|---|---|
Market Cap | $2.14B | $28.15B |
Volume | 30,789,535 | 1,351,262 |
Sector | Health | Consumer Cyclical |
52-Week High | $6.79 | $251.81 |
52-Week Low | $2.84 | $168.64 |
Typical Hold Time | 22 Days | 59 Days |
Enterprise Value | $1.66B | $28.65B |
Dividend Yield | — | 1.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $4.27, down 7.78% today, with technical indicators showing a bullish trend despite recent weakness. The company reported Q2 2026 earnings miss after two consecutive beats, with revenue declining to $54 million in 2026 from $74 million in 2025. While maintaining a negative net income margin of -961.97%, RXRX continues to expand its AI-powered drug discovery platform through strategic partnerships with Tempus and Roche.
The stock presents high-risk growth potential with strong analyst support (40% buy rating) but faces significant execution challenges. Investment appeal hinges on successful pipeline development and commercialization of AI drug discovery technology, though persistent losses and declining revenue create substantial downside risk for shareholders.
Williams-Sonoma (WSM) trades at $240.46, down 0.74% on the day, with a bullish technical signal and strong profitability metrics. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Recent news highlights market share gains, margin expansion, and new store openings, reinforcing positive business momentum.
The outlook remains favorable given earnings outperformance and raised guidance, though valuation multiples are elevated. Key risks include housing market sensitivity and competitive pressures. Analyst consensus is mixed but leans positive, with a price target suggesting modest upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Williams-Sonoma, Inc.
With a wide retail and direct-to-consumer presence, Williams-Sonoma is a leader in the $300 billion domestic home category, focused on expanding its exposure in the B2B, marketplace, and franchise areas. Namesake Williams-Sonoma (175 stores) offers high-end cooking essentials, while Pottery Barn (189) provides casual home accessories. Brand extensions include Pottery Barn Kids (52) and PBteen. West Elm (121) is an emerging concept for young professionals, and Rejuvenation (9) offers lighting and house parts. Williams-Sonoma also has a business-to-business team that supports projects that range from residential to large-scale commercial.
Read more on WSM →
